- Home
- SSII vs INBX Comparison
SSII vs INBX Comparison
Compare SSII & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSII | INBX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SSII | INBX |
|---|---|---|
| Price | $3.98 | $83.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 112.0K | ★ 193.3K |
| Earning Date | 03-20-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,066,457.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 158.36 | N/A |
| 52 Week Low | $3.02 | $10.81 |
| 52 Week High | $22.42 | $94.57 |
Technical Indicators
Market Signals| Indicator | SSII | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 29.30 | 60.30 |
| Support Level | $3.40 | $78.48 |
| Resistance Level | $6.01 | $88.00 |
| Average True Range (ATR) | 0.52 | 4.99 |
| MACD | -0.15 | 1.29 |
| Stochastic Oscillator | 11.46 | 82.59 |
Price Performance
Historical ComparisonAbout SSII SS Innovations International Inc.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.